Alnylam Pharmaceuticals, Inc. Overview
Pro stress-test →Alnylam is the pioneer of RNA interference (RNAi) technology and has successfully transitioned from a research-heavy enterprise to a fully integrated, profitable commercial leader. With the expansion of its flagship drug, Amvuttra, into the multi-billion-dollar Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM) market, the company is currently at the center of one of the most significant therapeutic shifts in modern medicine.
Strategic Profile
Pro stress-test →With a blockbuster product in Amvuttra, a clear path to sustained profitability, and a platform expanding into massive therapeutic areas like hypertension and Alzheimer's, Alnylam is a rare breed in the biotechnology sector. The company's new five-year strategy, "Alnylam 2030," focuses on scaling operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility.
Competitive Landscape
Pro stress-test →The "War of the TTRs" is the primary 2026 competitive narrative. Alnylam faces Pfizer (Vyndaqel as current market share leader), BridgeBio (Attruby as closest competitor), and Ionis/AstraZeneca (Wainua silencer with massive cardiovascular sales force). Alnylam's first-mover advantage and superior outcomes data position it as the company to beat.
Industry Context
Alnylam Pharmaceuticals, Inc. operates in Biopharmaceuticals - RNA Interference (RNAi) Therapeutics.
Key facts
Founded: 2002 · Headquarters: Cambridge, US · Revenue: $3.0B (2025)